Renal Cell Carcinoma | Current Treatment: Physician Insights | US | 2017

Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously treated metastatic renal cell carcinoma patients. This analysis provides insight on current use of approved therapies for renal cell carcinoma in the United States and on oncologists’ perception of these therapies.

Login to access report